Akoya Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	96.63	74.86	54.92	42.44	42.24
Revenue Growth (YoY)	29.09%	36.31%	29.39%	0.49%	-
Cost of Revenue	40.33	31.47	20.7	16.54	17.57
Gross Profit	56.31	43.39	34.22	25.91	24.66
Selling, General & Admin	82.38	79.65	51.02	23.98	26.35
Research & Development	21.89	23.21	15.7	9.6	8.76
Other Operating Expenses	8.07	6.73	4.73	3.82	3.06
Operating Expenses	112.34	109.6	71.44	37.4	38.17
Operating Income	-56.03	-66.21	-37.23	-11.49	-13.5
Interest Expense / Income	8.76	4.55	3.12	2.72	1.88
Other Expense / Income	-1.51	-0.24	2.74	2.45	-0.83
Pretax Income	-63.28	-70.52	-43.08	-16.66	-14.56
Income Tax	0.04	0.12	-0.14	0.04	0.19
Net Income	-63.32	-70.64	-42.94	-16.71	-14.75
Preferred Dividends	0	0	1.44	5.06	0
Net Income Common	-63.32	-70.64	-44.37	-21.76	-14.75
Shares Outstanding (Basic)	44	38	27	2	2
Shares Outstanding (Diluted)	44	38	27	2	2
Shares Change	17.72%	40.34%	1034.62%	4.15%	-
EPS (Basic)	-1.43	-1.87	-1.65	-9.18	-8.04
EPS (Diluted)	-1.43	-1.87	-1.65	-9.18	-8.04
Free Cash Flow	-54.55	-60.8	-41.16	-10.14	-16.65
Free Cash Flow Per Share	-1.23	-1.61	-1.53	-4.28	-7.31
Gross Margin	58.27%	57.96%	62.31%	61.04%	58.39%
Operating Margin	-57.98%	-88.44%	-67.78%	-27.08%	-31.97%
Profit Margin	-65.53%	-94.37%	-80.79%	-51.27%	-34.93%
Free Cash Flow Margin	-56.45%	-81.22%	-74.95%	-23.89%	-39.41%
EBITDA	-45.63	-58.82	-35.17	-10.13	-9.62
EBITDA Margin	-47.22%	-78.57%	-64.04%	-23.86%	-22.78%
Depreciation & Amortization	8.89	7.15	4.79	3.82	3.06
EBIT	-54.52	-65.96	-39.96	-13.94	-12.68
EBIT Margin	-56.42%	-88.12%	-72.76%	-32.85%	-30.01%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).